Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - 24/7 Wall St. Russell 20002,502.44 +0.30% FTSE 1009,953.60 -0.04% Nikkei 22552,743.00 -1.01% Stock Market Live March 24, 2026: S&P 500 (SPY) Under Pressure Again Investing S&P 5006,579.90 -0.18% Dow Jones46,338.00 +0.13% Nasdaq 10024,091.00 -0.55% Pfizer Could Hit $36 by Year-End as Analysts See 2- to-1 Payoff on Key Prostate Cancer Trial By Joel SouthPublished Mar 24, 10:52AM EDT Quick Read Pfizer (PFE) is trading ...